International Journal of Science and Research Archive
eISSN: 2582-8185
Cross Ref DOI: 10.30574/ijsra
Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

Understanding and managing the complications of chronic kidney disease: A comprehensive review

Vankodoth Sireesha [1,*], Bhavani Dhomakonda [1], Mekala Sai Charitha [1], Gadila Sushma [1], Boddu Shirisha [1] and T. Rama Rao [2]

[1] *Department of Pharm D, CMR College of Pharmacy, Hyderabad, India.*
[2] *Department of Pharmaceutical Sciences, CMR college of Pharmacy, Hyderabad, India.*

International Journal of Science and Research Archive, 2025, 15(03), 688-699

Publication history: Received on 11 April 2025; revised on 21 May 2025; accepted on 23 May 2025

Article DOI: https://doi.org/10.30574/ijsra.2025.15.3.1451

Abstract

A progressive illness, chronic kidney disease (CKD) is linked to several systemic consequences that raise morbidity and death. Anemia, fluid retention, renal osteodystrophy, cardiovascular disease (CVD), and sepsis are the main consequences of chronic kidney disease (CKD) that are highlighted in this study. Iron dysregulation and decreased erythropoietin production cause anemia, but water and sodium retention cause fluid overload. Unbalances in the metabolism of calcium, phosphate, and vitamin D are the main cause of renal osteodystrophy. Both conventional and CKD-specific risk factors contribute to CVD, the primary cause of death in CKD patients. Because of immunological failure, CKD also makes people more vulnerable to infections and sepsis. To enhance patient outcomes, early detection and focused therapy approaches—such as phosphate binders, erythropoiesis-stimulating medicines, and new drugs like SGLT2 inhibitors and HIF-PHIs—are crucial.

Keywords: Chronic Kidney Disease; Anemia; Fluid Retention; Renal Osteodystrophy; Hyperparathyroidism; Cardiovascular Disease; Sepsis.

1. Introduction

When the kidneys sustain damage and are unable to filter blood as effectively as they once did, chronic kidney disease (CKD) results.[1] Numerous detrimental clinical consequences, including cardiovascular events, kidney failure necessitating renal replacement treatment, death, and a generally low quality of life for survivors, are linked to chronic kidney disease (CKD).[2]

2. Anemia

An absolute decrease in the total quantity of red blood cells (RBCs) in circulation is referred to as anemia. Reduced hemoglobin concentration, hematocrit, or red blood cell count are all indicators of anemia. Anemia by itself should not be regarded as a diagnosis; rather, it is a test result that indicates the existence of illness or disease.

2.1. Mechanism

Hypoxia Inducible Factor System: In reaction to low oxygen levels, kidney cells primarily produce the hormone erythropoietin (EPO), which promotes the creation of red blood cells. The hypoxia-inducible factor (HIF) system, in particular HIF1, which is made up of HIF1α (which is oxygen-sensitive) and HIF1β (which is constantly expressed), controls its expression. PHD enzymes hydroxylate HIF1α and bind to the von Hippel-Lindau protein (pVHL) to destroy it under normal oxygen levels. HIF1α enhances EPO synthesis, stabilizes, and promotes gene transcription in hypoxia.

* Corresponding author: Vankodoth Sireesha

Reactive oxygen species and Factor Inhibiting HIF (FIH) also affect HIF activity. By stopping HIF1α degradation, medications known as HIF prolyl hydroxylase inhibitors (HIF-PHIs) increase the generation of EPO. Renal EPO synthesis is significantly influenced by HIF2α, whereas HIF3α probably suppresses HIF1α and HIF2α activity.[4][5]

EPO Production in CKD: EPO levels in chronic kidney disease (CKD) are abnormally low in relation to the severity of anemia, and they get worse when kidney function deteriorates below an eGFR of 30 ml/min/1.73 m^2. HIF activation and EPO gene expression are inhibited by reduced renal oxygen supply and maintained oxygen gradients. Hypoxia-induced EPO synthesis is further inhibited by inflammatory cytokines, including IL-1, TGF-β, and TNF-α, which are frequent in chronic kidney disease. Under stressful conditions, such as bleeding or high altitude, some patients continue to produce EPO, which may indicate reversibility. Others have functional EPO deficit, in which EPO resistance renders EPO levels ineffectual while being normal. This resistance could be caused by neocytolysis, antagonistic peptides, increased hepcidin, EPO receptor blockage, or cytokine-induced apoptosis. In order to better the therapy of anemia in CKD and increase endogenous EPO, research is being done on focusing on the HIF pathway.[6][7]

Iron metabolism: Beyond the synthesis of red blood cells, iron is crucial for an efficient erythropoietic response to EPO. It also plays important functions in energy metabolism, muscular oxygen transport, DNA repair, and enzymatic activity. Even in the absence of anemia, iron deficiency, which is frequent in CKD patients, should be treated because it affects outcomes. Hepcidin, which prevents iron release by decomposing ferroportin, limits and regulates dietary absorption. The majority of iron in the body is obtained by recycling old red blood cells. Hepcidin levels rise in CKD due to inflammation and impaired kidney function, which results in functional iron insufficiency. This is made worse by proinflammatory cytokines, which increase iron storage and decrease its availability. While HIF-1α and HIF-2α further control iron metabolism by encouraging iron absorption and lowering hepcidin production, EPO suppresses hepcidin via erythroferrone, increasing iron availability during stress erythropoiesis.[8][9]

2.2. Management

Erythropoiesis-Stimulating Agents: Epoetin alfa and darbepoetin alfa are two examples of erythropoiesis-stimulating agents (ESAs) that are used to treat anemia in chronic kidney disease (CKD), usually when hemoglobin falls below 10 g/dL. Because of its extended half-life, darbepoetin can be used less frequently. Alternatives include CERA, a longer-acting ESA, and epoetin alfa-epbx, a biosimilar. In order to prevent hazards including stroke, thrombosis, and mortality—all of which rise with greater ESA dosages—the target hemoglobin level with ESA medication is less than 11.5 g/dL. In 10–20% of cases, ESA resistance may develop, frequently as a result of iron insufficiency. Patients with a history of stroke or cancer are advised not to use ESA. ESA cessation or immunosuppressive treatment may be necessary in rare cases when ESAs produce pure red cell aplasia as a result of anti-erythropoietin antibodies, particularly when administered subcutaneously.[10][11]

Treatment with Iron: Because of poor absorption, ongoing bleeding, and dialysis losses, iron deficiency is frequent in CKD. Supplementation is necessary since ESA therapy raises the demand for iron. IV iron is recommended because elevated hepcidin levels hinder absorption, particularly in advanced chronic kidney disease. Ferritin should be kept below 500–800 ng/mL and TSAT between 20–30%, according to KDIGO and other guidelines. The PIVOTAL experiment, on the other hand, demonstrated improved results without an elevated risk of infection, supporting more liberal limits (TSAT 40%, ferritin 700 ng/mL). Although infection and iron overload are potential hazards, the evidence is still conflicting. Although rare, anaphylaxis can occur with IV formulations. Because of their stable carbohydrate shells and decreased oxidative stress, new-generation IV irons, such as ferrumoxytol and ferric derisomaltose, provide increased safety. They make it possible to administer bigger, less frequent doses, which enhances tolerance and convenience while treating anemia linked to CKD.[12][13]

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors: A novel class of medications known as HIF-prolyl hydroxylase inhibitors (HIF-PHIs) stabilizes HIF levels to boost the production of erythropoietin. Hepcidin levels are likewise lowered by these substances. Daprodustat received FDA approval in 2023 for use in dialysis patients, but not in non-dialysis patients. Other medications in this class are used overseas. HIF-PHIs are oral drugs, in contrast to ESAs. Although no such impacts have been shown in dialysis patients, preliminary research points to a possible rise in cardiovascular events in non-dialysis-dependent CKD patients. Similar to ESAs, HIF-PHIs have the potential to aggravate retinal or polycystic kidney disease and promote cancer because of their angiogenesis-related actions. Since the class is relatively new, research on the long-term safety profile is still ongoing.[14][15]

Ziltivekimab: A human immunoglobulin G (IgG) monoclonal antibody called ziltivekimab targets the inflammatory cytokine interleukin (IL)-6. When compared to a placebo, ziltivekimab has been shown to enhance iron indices, raise

albumin and hemoglobin levels, and decrease inflammation in patients with CKD stages 3 to 5. Increased hepcidin expression is linked to IL-6, which could account for ziltivekimab's therapeutic advantages.[16][17]

3. Fluid retention

An excessive buildup of fluid in the body, frequently due to an imbalance between fluid intake and disposal, is referred to as fluid overload in the kidney. Numerous health issues, such as edema (swelling), dyspnea, and elevated heart and blood vessel pressure, may result from this.

3.1. Mechanism

Underfill theory: The traditional "underfill" theory states that hypovolemia causes sodium retention in nephrotic syndrome (NS), with urine protein losses resulting in reduced plasma albumin and oncotic pressure. Fluid moves from the intravascular to the interstitial space as a result, decreasing the effective arterial blood volume and causing neurohumoral reactions such as RAAS and sympathetic nervous system activation, which encourage edema and sodium retention. However, as many edematous NS patients have normal or expanded intravascular volume, clinical data cast doubt on this notion. Some rats and humans without albumin do not develop edema, demonstrating that hypoalbuminemia alone is not sufficient to explain edema. These results imply that sodium retention in NS might happen without regard to volume depletion.[18][19]

Overfill theory: Instead of volume depletion as in the "underfill" hypothesis, the "overfill" hypothesis suggests that nephrotic syndrome (NS) is caused by a basic deficiency in salt and water excretion. According to this theory, increased tubular sodium reabsorption brought on by proteinuria results in an increase in the volume of extracellular fluid and the development of edema. Primary sodium retention in NS is caused by the following mechanisms:

- Tubular albumin activates the Na+/H+ exchanger 3 (NHE3) in the proximal tubules.
- The collecting ducts' Na, K-ATPase pump is stimulated by proteinuria.
- Urine proteases (plasminogen/plasmin) activate amiloride-sensitive sodium channels (ENa+C) in the collecting ducts.
- Tubular resistance to ANP as a result of cGMP depletion and elevated cGMP phosphodiesterase activity.

In NS, these mechanisms lead to edema and salt retention.[20][21]

3.2. Management

Focusing on lowering sodium and fluid consumption and utilizing diuretics to aid the body in eliminating extra fluid, managing fluid retention in Chronic Kidney Disease (CKD) entails a combination of dietary modifications, medication, and, in certain situations, dialysis.[22]

3.3. Dietary Modifications

- Reduce Your Sodium Consumption - Cutting back on salt is essential because sodium makes the body retain water.[23]
- Limit the Consumption of Fluids - Your healthcare provider may advise restricting fluid consumption to avoid fluid overload, depending on the stage of chronic kidney disease.[23]
- Adhere to a Renal Diet - You can develop a customized meal plan with the assistance of a trained dietitian that takes into account your unique requirements.[24]
- Watch Out for Hidden Sodium - Pay close attention to food labels because many processed foods contain hidden salt.[24]

3.4. Medications

- Diuretics - These drugs, also referred to as "water pills," assist the body in excreting extra fluid and sodium through urine.[22]
- Angiotensin II Receptor Blockers - These drugs lessen water and salt retention by relaxing and enlarging blood vessels.[25]
- Dialysis: When the kidneys are unable to adequately filter the blood and eliminate waste materials and excess fluid in severe stages of chronic renal disease, dialysis may be required.[22]

3.5. Changes in lifestyle

- Regular physical activity - Regular exercise, as recommended by a medical practitioner, can help control blood pressure and preserve general health.
- Controlling Thirst - Your dietician can recommend thirst-control techniques like sugar free hard candies or ice chips if you struggle to manage your fluid intake.[23]
- Monitor Fluid Intake - Maintaining a log of your fluid intake will enable you to track your development and make necessary corrections.[23]
- Avoid Skipping Dialysis Sessions - To guarantee appropriate fluid and waste clearance, it is crucial for dialysis patients to attend all of their scheduled treatments.[24]

4. Renal osteodystrophy

Children and adults with chronic kidney illness can develop renal osteodystrophy, a bone disease. The calcium and phosphorus mineral levels in your blood are controlled in part by your kidneys. In order to maintain strong and healthy bones, they also activate vitamin D to produce the calcitriol hormone. Your kidneys are unable to maintain appropriate amounts of these minerals and the hormone calcitriol when they are failing or not performing as well. Fractures may result from this weakening of your bones.[26]

Calcium, Phosphorus, Calcitriol, Fibroblast growth factor(FSF), Parathyroid Hormone are important minerals and hormones for bone health.

Impaired kidney function in Chronic Kidney condition (CKD) causes calcium imbalances, including decreased absorption and retention, which exacerbates renal osteodystrophy, a bone condition marked by weakening and discomfort in the bones.[27][52]

Reduced Vitamin D Activation and Kidney Function: The conversion of inert vitamin D into its active form, calcitriol, which is necessary for the intestinal absorption of calcium, is a critical function of healthy kidneys. [28]

The kidneys' capacity to activate vitamin D is diminished in chronic kidney disease (CKD), which lowers calcitriol levels and, in turn, reduces the absorption of calcium from the gut.[28]

Calcium Depletion and Phosphate Retention: Hyperphosphatemia (high phosphate levels in the blood) results from damaged kidneys' inability to eliminate excess phosphate from the body. [29] Low blood calcium levels, or hypocalcemia, can result from elevated phosphate levels binding to calcium and reducing its availability.[29] Weakened bones and bone loss result from the body's attempt to make up for low calcium levels by taking calcium from bones.[29][53]

Secondary Hyperparathyroidism: The parathyroid glands release parathyroid hormone (PTH) to keep blood calcium levels stable.[26] The kidneys' incapacity to control vitamin D and phosphate levels causes chronically low calcium and high phosphate in CKD, which in turn causes the parathyroid glands to overproduce PTH.[30] Increased bone resorption, or disintegration, results from this overproduction of PTH, further weakening bones.[30]

Renal osteodystrophy is a bone disease caused by a combination of secondary hyperparathyroidism, phosphate retention, and decreased calcium absorption. It is characterized by:[30]

- Weakened bones: As a result of bone deterioration and calcium loss.[29]
- Fractures and bone pain: Weakened bones increase the chance of fractures.[26]
- Bone deformities: Severe CKD can cause abnormalities of the bones.[29]
- Vascular Calcification: When CKD patients have abnormalities in their mineral metabolism, blood vessels may calcify, raising their risk of cardiovascular disease.[31]

4.1. Management

Restoring mineral and hormone balance is the main goal of treatment for renal osteodystrophy. Medication for this condition includes vitamin D supplements and phosphate binders, as well as dietary modifications and, in certain situations, dialysis or surgery.[26]

4.2. Dietary adjustments

- Diet low in phosphorus - It's critical to limit phosphorus-rich foods including processed foods, dairy products, and specific veggies.[26]
- Binders made of phosphate - These drugs, such as calcium acetate or carbonate, attach to phosphorus in the stomach and stop it from entering the bloodstream.[26]
- Non-calcium phosphate binders - Non-calcium phosphate binders, such as sevelamer or lanthanum carbonate, are used to lower phosphorus levels in patients with elevated calcium levels without raising calcium levels.[32]

4.3. Supplements and Medications

- Vitamin D Supplements - Calcium absorption depends on vitamin D, which is activated by the kidneys. Low levels of vitamin D may result from the kidneys' inability to properly activate it in renal osteodystrophy.[26]
- Calcitriol - Low vitamin D levels can be treated with this active form of vitamin D, which also helps to strengthen bones.[32]
- Medications that lowers parathyroid hormones - Drugs such as cinacalcet can help reduce increased parathyroid hormone levels.[26]

4.4. Parathyroid Surgery

Parathyroidectomy - Surgery to remove one or more of the parathyroid glands (parathyroidectomy) may be required to lower parathyroid hormone levels in extreme cases if other treatments are not working.[26]

4.5. Dialysis

Hemodialysis - Dialysis can assist manage mineral and bone abnormalities in patients with end-stage kidney disease by removing waste products and excess fluids from the blood, including phosphorus.[22]

4.6. Other Considerations

Early Precaution - Even when kidney function is still comparatively strong, early treatment of renal osteodystrophy can help avoid or slow down bone deterioration.[32]

Frequent observation - To make sure that treatment is working and to make any adjustments, it is crucial to regularly check the levels of calcium, phosphorus, and parathyroid hormone.[26]

Transplantation of kidneys - A kidney transplant can help control renal osteodystrophy and restore kidney function in patients with end-stage kidney disease.[32]

5. Cardiovascular disease

The risk of cardiovascular disease (CVD), which is the primary cause of death for patients with chronic kidney disease (CKD), is greatly increased by CKD. Compared to the general population, patients with chronic kidney disease (CKD) are more likely to experience cardiovascular events such as heart failure, arrhythmias, coronary artery disease, stroke, and sudden cardiac death. The influence of chronic kidney disease (CKD) on cardiovascular risk is significant even after adjusting for conventional CVD risk factors including diabetes and hypertension.[33]

5.1. Mechanism

Risk factors specific to CKD - In addition to conventional risk factors, CKD is linked to a number of variables that raise the risk of CVD, including as oxidative stress, inflammation, anemia, and uremia.[34]

Myocardial and Vascular Alterations - Atherosclerosis, vascular calcification, and myocardial fibrosis are all consequences of vascular and cardiac remodeling brought on by chronic kidney disease.[35]

Increased Aging - Early start and progression of cardiovascular disease (CVD) can result from CKD's acceleration of the cardiovascular system's aging process.[35]

5.2. Management

Managing cardiovascular disease (CVD) in people with chronic kidney disease (CKD) requires a multimodal strategy that emphasizes managing risk factors unique to CKD, regulating conventional risk factors, and employing drugs and

procedures as necessary. Aggressive blood pressure treatment, statin-assisted lipid management, glycemic control, and addressing additional risk factors such as inflammation, anemia, and hyperparathyroidism are important tactics.[36]

5.2.1. Management of Risk Factors

- Control of Blood Pressure - One of the main causes of CVD, hypertension, is more likely to occur in CKD patients. It is essential to lower blood pressure with drugs such as ACE inhibitors, ARBs, and other antihypertensives.[37]
- Control of Glycemic - One important risk factor for both CVD and CKD is diabetes mellitus. For diabetic CKD patients, strict glycemic control is crucial.[36]
- Control of Lipids - To lower LDL cholesterol and lower the risk of CVD, statins are advised for all CKD patients over 50 and with an eGFR more than 60 mL/min.[37]
- Quitting Smoking - All CKD patients should have their smoking cessation since it is a significant risk factor for CVD.[36]
- Controlling Weight - A risk factor for both CVD and CKD is obesity. Losing weight can be advantageous.[36]
- Changes in Diet - For both CKD and CVD, a nutritious diet low in sodium, phosphorus, and potassium can be helpful.[36]

5.2.2. Resolving Risk Factors Particular to CKD

- Hyperphosphatemia - In CKD, elevated phosphorus levels may be a contributing factor to CVD. Phosphate binders and dietary restrictions could be required.
- Hyperkalemia - Elevated potassium levels should be controlled since they can be harmful to the heart.
- Anemia - Anemia can exacerbate CVD and is prevalent in CKD. Erythropoiesis-stimulating agents (ESAs) and iron therapy may be required.
- Inflammation - One of the main causes of CVD is inflammation, which can be made worse by CKD. ARBs and ACE inhibitors have anti-inflammatory properties.[36]

5.2.3. Drug-Related Interventions

- SGLT2 Inhibitors - According to studies, SGLT2 inhibitors, which were first used for diabetes, can lower cardiovascular events and decrease the course of CKD in individuals who also have diabetes.[36]
- Renin Angiotensin Aldosterone System blockade - ARBs and ACE inhibitors help lower the risk of CVD and decrease the course of CKD.
- Beta Blockers - Some CKD patients with CVD, especially heart failure, may benefit from it.
- Calcium Channel Blockers - Suitable for use with hypertension and other cardiovascular diseases.
- Antiplatelet Treatment - In CKD patients, aspirin and other antiplatelet drugs are utilized for secondary CVD prevention.
- Additional Drugs - Depending on the demands of each patient, diuretics, mineralocorticoid receptor antagonists (MRAs), and other drugs may be employed.

5.2.4. Intervention Techniques

- Cardiovascular Percutaneous Intervention (PCI) - may be used to treat CKD patients' coronary artery disease.
- Coronary Artery Bypass Graft (CABG) - may be recommended for dialysis patients with significant coronary artery disease.
- Renal Transplantation - Patients with CKD may have better cardiovascular outcomes after receiving a renal transplant.

5.2.5. Changes in Lifestyle

- Regular Exercise - Engaging in physical activity can enhance general health and cardiovascular health.
- Quitting Smoking - Giving up smoking is essential for heart health.
- Management of Weight - CVD risk can be decreased by maintaining a healthy weight.
- Reduction of Stress - Cardiovascular health can be enhanced by stress management.[38]

In summary, a comprehensive strategy that tackles both conventional and CKD-specific risk factors, makes use of the right pharmaceutical therapies, promotes lifestyle changes, and takes into account interventional procedures where necessary is needed to manage CVD in CKD.[37]

6. Sepsis

Chronic kidney disease (CKD) and sepsis are closely related conditions that raise the risk of one another. People with CKD are especially vulnerable to infections that might cause sepsis because their immune systems are weakened. On the other hand, sepsis can result in acute kidney injury (AKI), which can cause chronic renal disease if left untreated.[39] Because of their compromised immune systems, vascular access points for dialysis, and frequent hospital stays, people with chronic kidney disease (CKD), particularly those receiving dialysis, are more susceptible to sepsis.[40] AKI and kidney failure may result from the inflammation that sepsis causes throughout the body.[41] Sepsis-induced AKI can evolve into chronic kidney disease (CKD), which further impairs immunity and raises the risk of sepsis and infections in the future.[39] Vascular access points, such as catheters, grafts, or fistulas, can act as entry portals for bacteria, increasing the risk of sepsis in dialysis patients.[41] The death rate is higher for patients who have both sepsis and AKI, particularly those who also have CKD.[39] For CKD patients to have better results, sepsis and AKI must be identified and treated early.[41] Because of the possibility of volume overload and altered circulatory responses to vasopressors, fluid management in patients with CKD and sepsis can be challenging.[42]



[43]

Figure 1 Pathophysiology of sepsis induced acute kidney injury (AKI).

6.1. Mechanism

A complex interaction of variables, such as dysregulated immunological responses, decreased renal perfusion, and microvascular dysfunction, can lead to sepsis in people with Chronic Kidney Disease (CKD). These problems are made worse in CKD by pre-existing kidney impairment, which can make sepsis-induced acute kidney injury (AKI) more severe.[43]

Immune Response and Inflammation - In a systemic inflammatory response brought on by sepsis, innate immune cells are activated by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). This reaction is frequently heightened in CKD, which may result in a cytokine storm and further tissue damage.[44]

Hemodynamics and Perfusion in the Renal System - In patients with chronic kidney disease (CKD), where the kidneys are already damaged, sepsis can lead to hypotension and decreased renal blood flow (RBF). AKI can deteriorate due to ischemia and injury to renal tubular epithelial cells caused by reduced RBF.[45]

Microvascular Impairment - The kidneys' microvasculature may be disturbed by sepsis, which could result in increased permeability and poor oxygen supply. In CKD, when microvascular alterations are already common, this is especially problematic.[44]

Reduced Capacity to Handle Fluids - Patients with chronic kidney disease (CKD) may struggle to control their fluid intake, which can exacerbate venous congestion and lead to AKI.[43]

Enhanced susceptibility - Patients with CKD are more prone to sepsis because they frequently have impaired immune systems and are more likely to have infections.[46]

Pre existing Kidney Damage - Sepsis can worsen the impact of sepsis on renal function in patients with chronic kidney disease (CKD) who already have structural and functional damage in their kidneys.[47]

High Mobility Group Box 1 (HMGB1) and Vascular Endothelial Growth Factor (VEGF) - It has been demonstrated that elevated VEGF and HMGB1 levels in sepsis are magnified in CKD-sepsis models, which leads to increased vascular permeability and other organ damage.[47]

6.2. Management

A multidisciplinary strategy is necessary to manage sepsis in patients with chronic kidney disease (CKD), with an emphasis on quick identification, intensive fluid resuscitation, timely antibiotic treatment, and supportive care to address potential consequences such acute kidney injury (AKI). In the event that sepsis-induced AKI occurs, dialysis might be required.[41]

6.2.1. Prompt Identification and Diagnosis

- Criteria for Sepsis - To identify individuals at risk for sepsis, particularly those with chronic kidney disease (CKD), use recognized criteria (e.g., qSOFA, SOFA score).[46]
- Symptoms and Indications - Keep an eye out for symptoms of sepsis (low blood pressure, fast breathing, reduced oxygen saturation) and infection (fever, chills, elevated heart rate, altered mental status).[48]

6.2.2. Fast Intervention

- Antibiotics - When sepsis is suspected, give broad-spectrum antibiotics within the first hour, especially to patients who are in shock.[43]
- Resuscitation of Fluids - In order to maintain blood pressure and perfusion, aggressive fluid resuscitation—such as crystalloid boluses—is essential. However, it should be continuously monitored and guided by the patient's response to prevent volume overload, particularly in patients with advanced chronic kidney disease.[49]
- Vasopressors - It can be necessary to use vasopressors, such as norepinephrine, to support blood pressure if hypotension continues after fluid resuscitation.[50]
- Control of the Source - As quickly as feasible, take care of the infection's source (draining abscesses, removing contaminated gadgets, etc.).[50]

6.2.3. Supportive Care

- Oxygenation - Keep an eye on oxygen saturation and give more oxygen when required.[46]
- Using mechanical ventilation - Mechanical ventilation might be required if respiratory failure occurs.[49]\
- Blood Sugar Regulation - Control blood sugar levels to avoid problems.[46]
- Dialysis - Dialysis might be necessary to control fluid overload and filter toxins if sepsis-induced AKI manifests.[41]
- Additional Drugs - Certain problems may be treated with additional drugs (such as anticoagulants or drugs to control electrolyte imbalances).[48]

6.2.4. Monitoring and Management of Complications

- Acute Kidney Injury - Keep a close eye on renal function (e.g., urine output, serum creatinine) and watch for AKI.[46]
- Overload of Fluids - Avoiding fluid overload, which exacerbates AKI, is especially important for individuals with severe CKD.
- Disturbances in Electrolytes - Keep an eye on electrolyte levels (such as calcium and potassium) and adjust any imbalances as necessary.[46]
- Coagulopathy - Check for and treat any potential coagulopathy.[46]
- Additional Organ Failure - Keep an eye out for and treat additional organ failure, such as respiratory or liver issues.[48]

6.2.5. Customized Methodology

- Stage of CKD - When choosing dialysis and fluid resuscitation, take the patient's CKD stage into account.[42]
- Fluidity of Response - Evaluate fluid response and adjust fluid administration for each individual.[42]
- Previous Health Issues - Consider any underlying medical disorders that may affect the therapy of sepsis, such as diabetes or cardiovascular disease.[51]

7. Conclusion

Anemia, fluid overload, renal osteodystrophy, cardiovascular disease, sepsis, and other main consequences of chronic kidney disease (CKD) are highlighted in this thorough overview along with their underlying processes and therapy approaches. The study highlights the value of integrated care in enhancing patient outcomes by stressing early detection, targeted medicines, and lifestyle changes. This review helps healthcare practitioners optimize the management of chronic kidney disease (CKD) and sets the stage for future research aimed at improving quality of life and lowering the burden of disease in the general population by combining the most recent data and therapeutic methods.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Martin, Cory. "Complications of Chronic Kidney Disease." *verywellhealth*, 19 September 2023, https://www.verywellhealth.com/complications-of-ckd-5223123.

[2] Alkhaqani, A. L. (2022). Risk Factors and Complications of Chronic Kidney Disease: Narrative Review . *Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219)*, *2*, 107–114. https://doi.org/10.54133/ajms.v2i.68

[3] Colbert, Gates B. "Anemia of Chronic Disease and Kidney Failure." *medscape*, 23 December 2024. https://emedicine.medscape.com/article/1389854-overview?st=fpf&scode=msp&socialSite=google&form=fpf&icd=login_success_gg_match_fpf#a1.

[4] Kaplan JM, Sharma N, Dikdan S. Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease. *Int J Mol Sci*. (2018) 19:389. doi: 10.3390/ijms19020389

[5] Pan X, Suzuki N, Hirano I, Yamazaki S, Minegishi N, Yamamoto M. Isolation and characterization of renal erythropoietin- producing cells from genetically produced anemia mice. *PLoS ONE*. (2011) 6:e0025839. doi: 10.1371/journal.pone.0025839

[6] Fandrey J, Jelmann WE. Interleukin-1 and tumor necrosis factor-alpha inhibit erythropoietin production *in vitro*. *Ann N Y Acad Sci*. (1991) 628:250–5. doi: 10.1111/j.1749-6632.1991.tb17252.x

[7] Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W. Neocytolysis contributes to the anemia of renal disease. *AJKD*. (1999) 33:59–62. doi: 10.1016/S0272-6386(99)70258-1

[8] van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. *Nat Rev Nephrol*. (2020) 16:77–98. doi: 10.1038/s41581-019-0197-5

[9] Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). *J Clin Invest*. (2007) 117:1926–32. doi: 10.1172/JCI31370

[10] Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U., ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008 Mar;3(2):337-47.

[11] Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis. 2018 Mar;71(3):423-435.

[12] Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, Małyszko J, Swinkels DW, Tarng DC, Cheung M, Jadoul M, Winkelmayer WC, Drüeke TB., Conference Participants. Controversies in optimal anemia

management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2021 Jun;99(6):1280-1295.

[13] Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S., Dialysis Advisory Group of the American Society of Nephrology. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015 Jun;26(6):1238-47.

[14] Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V., ASCEND-ND Study Group. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 Dec 16;385(25):2313-2324.

[15] Xu Q, Huang J, Liu Q, Wang X, Liu H, Song Y, Dou F, Lv S, Liu G. Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis. Front Endocrinol (Lausanne). 2024; 15:1372150.

[16] Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2021 Jan; 32(1):211-222.

[17] Badura K, Janc J, Wąsik J, Gnitecki S, Skwira S, Młynarska E, Rysz J, Franczyk B. Anemia of Chronic Kidney Disease-A Narrative Review of Its Pathophysiology, Diagnosis, and Management. Biomedicines. 2024 May 27;12(6)

[18] Lecomte J. Juchmès J. [So-called absence of edema in analbuminemia]. *Rev Med Liege.* 1978; 33(21): 766–770.

[19] Koomans H.A. Geers A.B. vd Meiracker A.H. Roos J.C. Boer P. Dorhout Mees E.J. Effects of plasma volume expansion on renal salt handling in patients with the nephritic syndrome. *Am J Nephrol.* 1984; 4(4): 227–234.

[20] Klisic J. Zhang J. Nief V. Reyes L. Moe OW Ambuhl P.M. Albumin regulates the Na+/H+ exhanger in OKP cells. *J Am Soc Nephrol.* 2003; 14(12): 3008–3016.

[21] Besse-Eschmann V. Klisic J. Nief V. Le Hir M. Kaissling B. Ambuhl P. Regulation of the proximal tubular sodium/proton exchanger NHE3 in rats with puromycin aminonucleoside (PAN) induced nephrotic syndrome. *J Am Soc Nephrol.* 2002; 13(9): 2199–2206.

[22] "Chronic kidney disease - Diagnosis and treatment." *Mayo Clinic*, 6 September 2023, https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527. Accessed 10 April 2025.

[23] "Fluid Overload in a Dialysis Patient." *National Kidney Foundation*, https://www.kidney.org/kidney-topics/fluid-overload-dialysis-patient. Accessed 10 April 2025.

[24] "Managing Swelling Caused by Kidney Disease | CKD Symptoms." *Fresenius Kidney Care*, https://www.freseniuskidneycare.com/thrive-central/handling-kidney-disease-swelling. Accessed 10 April 2025.

[25] "Medication for Cardiomyopathy & Heart Failure." *NYU Langone Health*, https://nyulangone.org/conditions/cardiomyopathy-heart-failure/treatments/medication-for-cardiomyopathy-heart-failure. Accessed 10 April 2025.

[26] "Renal Osteodystrophy: Causes, Symptoms & Treatment." *Cleveland Clinic*, https://my.clevelandclinic.org/health/diseases/24006-renal-osteodystrophy. Accessed 10 April 2025.

[27] Ko E, Omolehinwa T, Akintoye SO, Mupparapu M. Radiographic diagnosis of systemic diseases manifested in jaws. Dental Clinics. 2021 Jul 1;65(3):579-604.

[28] "Kidney Failure Risk Factor: Serum Calcium." *National Kidney Foundation*, https://www.kidney.org/kidney-failure-risk-factor-serum-calcium. Accessed 10 April 2025.

[29] "Mineral & Bone Disorder in Chronic Kidney Disease - NIDDK." *National Institute of Diabetes and Digestive and Kidney Diseases*, https://www.niddk.nih.gov/health-information/kidney-disease/mineral-bone-disorder. Accessed 10 April 2025.

[30] Shah A, Hashmi MF, Aeddula NR. Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) [Updated 2024 Apr 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560742/

[31] Arcidiacono T, Paloschi V, Rainone F, Terranegra A, Dogliotti E, Aloia A, Soldati L, Vezzoli G. Renal osteodystrophy and vascular calcification. J Endocrinol Invest. 2009;32(4 Suppl):21-6. PMID: 19724162.

[32] Malluche HH, Mawad H, Monier-Faugere MC. Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S157-63. doi: 10.2215/CJN.02500607. PMID: 18988701; PMCID: PMC3152281.

[33] Saeed D, Reza T, Shahzad MW, Karim Mandokhail A, Bakht D, Qizilbash FH, Silloca-Cabana EO, Ramadhan A, Bokhari SFH. Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health. Cureus. 2023 Dec 30;15(12):e51362. doi: 10.7759/cureus.51362. PMID: 38292979; PMCID: PMC10825078.

[34] Zhang, Yimeng, and Nimai Desai. "CVD in CKD: An Introduction | Chronic Kidney Disease." *European Cardiology Review*, 13 May 2022, https://www.ecrjournal.com/articles/cardiovascular-complications-chronic-kidney-disease-introduction?language_content_entity=en. Accessed 12 April 2025.

[35] Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021 Mar 16;143(11):1157-1172. doi: 10.1161/CIRCULATIONAHA.120.050686. Epub 2021 Mar 15. PMID: 33720773; PMCID: PMC7969169.

[36] Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr Cardiol Rev. 2019;15(1):55-63. doi: 10.2174/1573403X14666180711124825. PMID: 29992892; PMCID: PMC6367692.

[37] Ulu, S., Onan, E. (2023). Management of Cardiovascular Disease in Chronic Kidney Disease. In: Arıcı, M. (eds) Management of Chronic Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-42045-0_13

[38] Matthew P M Graham-Brown, Alice C Smith, Sharlene A Greenwood, Digital health interventions in chronic kidney disease: levelling the playing field?, *Clinical Kidney Journal*, Volume 16, Issue 5, May 2023, Pages 763–767, https://doi.org/10.1093/ckj/sfac259

[39] Flannery AH, Li X, Delozier NL, Toto RD, Moe OW, Yee J, Neyra JA. Sepsis-Associated Acute Kidney Disease and Long-term Kidney Outcomes. Kidney Med. 2021 Apr 16;3(4):507-514.e1. doi: 10.1016/j.xkme.2021.02.007. PMID: 34401718; PMCID: PMC8350838.

[40] "Sepsis." *Kidney Care UK*, https://kidneycareuk.org/kidney-disease-information/kidney-conditions/sepsis/. Accessed 12 April 2025.

[41] "Sepsis - Symptoms, causes, complications, and treatment." *National Kidney Foundation*, https://www.kidney.org/kidney-topics/sepsis. Accessed 12 April 2025.

[42] Jorda, A., Douglas, I.S., Staudinger, T. *et al.* Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial. *Crit Care* 28, 231 (2024). https://doi.org/10.1186/s13054-024-05019-6

[43] Patel S, Puri N, Dellinger RP. Sepsis Management for the Nephrologist. Clin J Am Soc Nephrol. 2022 Jun;17(6):880-889. doi: 10.2215/CJN.14381121. Epub 2022 May 12. PMID: 35551069; PMCID: PMC9269656.

[44] Balkrishna A, Sinha S, Kumar A, Arya V, Gautam AK, Valis M, Kuca K, Kumar D, Amarowicz R. Sepsis-mediated renal dysfunction: Pathophysiology, biomarkers and role of phytoconstituents in its management. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:115183.

[45] Gómez H, Kellum JA. Sepsis-induced acute kidney injury. Curr Opin Crit Care. 2016 Dec;22(6):546-553. doi: 10.1097/MCC.0000000000000356. PMID: 27661757; PMCID: PMC5654474.

[46] Varma, Avi. "Kidney Failure Sepsis: Symptoms, Risks, Treatment, Recovery." *Healthline*, 1 May 2023, https://www.healthline.com/health/kidney-disease/kidney-failure-sepsis. Accessed 12 April 2025.

[47] Doi K, Leelahavanichkul A, Hu X, Sidransky KL, Zhou H, Qin Y, Eisner C, Schnermann J, Yuen PS, Star RA. Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int. 2008 Oct;74(8):1017-25. doi: 10.1038/ki.2008.346. Epub 2008 Jul 16. PMID: 18633340; PMCID: PMC2614371.

[48] "Sepsis: Symptoms, Causes, Treatment & Prevention." *Cleveland Clinic*, 19 January 2023, https://my.clevelandclinic.org/health/diseases/12361-sepsis. Accessed 12 April 2025.

[49] Haley M, Foroutan NK, Gronquist JM, Reddy R, Wusirika R, Khan A. Fluid resuscitation and sepsis management in patients with chronic kidney disease or end-stage renal disease: scoping review. American Journal of Critical Care. 2024 Jan 1;33(1):45-53.

[50] Kalil, Andre, and David A. Kaufman. "Septic Shock Treatment & Management: Approach Considerations, Goals of Hemodynamic Support, Fluid Resuscitation." *Medscape Reference*, 26 June 2024, https://emedicine.medscape.com/article/168402-treatment#d11. Accessed 12 April 2025.

[51] Guarino M, Perna B, Cesaro AE, Maritati M, Spampinato MD, Contini C, De Giorgio R. 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department. J Clin Med. 2023 Apr 28;12(9):3188. doi: 10.3390/jcm12093188. PMID: 37176628; PMCID: PMC10179263.

[52] Sireesha, V. (2024). Comprehensive Review of CKD-MBD: From diagnosis to Therapeutic Interventions. *International Journal of Science and Healthcare Research*, *9*(3), 2455–7587. https://doi.org/10.52403/ijshr.20240335

[53] Neerudi, L., Atla, K., Konduri, G., & Vankodoth, S. (2022). Association between bone mineral density and chronic kidney disease: recent perspective. *International Journal of Pharmaceutical Sciences Review and Research*, 127–135. https://doi.org/10.47583/ijpsrr.2022.v73i01.021